Partners Capital Investment Group LLP Buys New Position in Bristol Myers Squibb Company $BMY

Partners Capital Investment Group LLP bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 60,405 shares of the biopharmaceutical company’s stock, valued at approximately $3,481,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC boosted its position in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC boosted its position in shares of Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares in the last quarter. United Bank grew its stake in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares during the period. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $221,000. Finally, Nebula Research & Development LLC bought a new stake in Bristol Myers Squibb in the second quarter worth approximately $405,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on BMY shares. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Truist Financial reiterated a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Raymond James Financial assumed coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a report on Friday, July 31st. Finally, Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Stock Up 0.4%

Shares of NYSE:BMY opened at $67.30 on Tuesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The business’s 50 day simple moving average is $60.77 and its two-hundred day simple moving average is $59.47. The firm has a market cap of $137.47 billion, a P/E ratio of 14.82, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the previous year, the company posted $1.46 earnings per share. The company’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.